• Something wrong with this record ?

The impact of Angiotensin II Type 1 Receptor antibodies on morbidity and mortality in Heart Mate II supported recipients

M. Urban, A. Slavcev, T. Gazdic, P. Ivak, I. Netuka

. 2016 ; 160 (4) : 518-523. [pub] 20160427

Language English Country Czech Republic

Document type Journal Article, Observational Study

Persistent link   https://www.medvik.cz/link/bmc17016698

AIMS: One of the proposed limitations of left ventricular assist device (LVAD) therapy is high degree of sensitization. Apart from human leukocyte antigen (HLA), antibodies against Angiotensin II Type 1 Receptor (AT1R) have been associated with adverse outcomes. The purpose of this study was to compare complications and survival of anti - AT1R positive versus negative Heart Mate II (HMII) recipients. METHODS: Altogether 96 patients received HMII at our institution between 2008 and 2012. These were stratified into three groups: antibody positive before implantation (AT1R+), antibody conversion during support (AT1R-/+) and patients who remained antibody negative (AT1R-). Survival, major on-device adverse events and post-transplant rejections were assessed with Kaplan-Meier and log-rank tests. RESULTS: Two year on-device and overall survival was 78 ± 12% and 75 ± 10% in AT1R-, 60 ± 23% and 60 ± 15% in AT1R+ and 92 ± 6% and 87 ± 5% in AT1R-/+ group (P = 0.409, P = 0.185). Freedom from major adverse event at two years for AT1R-, AT1R+ and AT1R-/+ was 49 ± 14%, 53 ± 16% and 41 ± 11% (P = 0.875). Freedom from rejection was 63 ± 17% in patients who were both anti-AT1R and HLA negative and 65 ± 13% in those who were antibody positive (P = 0.788). CONCLUSION: Patients who were anti-AT1R antibody positive had similar on-device survival and rate of complications in comparison to those who were antibody negative. In transplanted patients, there were no differences in the overall survival and rejection between the groups.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17016698
003      
CZ-PrNML
005      
20170519133914.0
007      
ta
008      
170516s2016 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2016.025 $2 doi
035    __
$a (PubMed)27132810
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Urban, Marian $u Department of Cardiac Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $7 xx0311158
245    14
$a The impact of Angiotensin II Type 1 Receptor antibodies on morbidity and mortality in Heart Mate II supported recipients / $c M. Urban, A. Slavcev, T. Gazdic, P. Ivak, I. Netuka
520    9_
$a AIMS: One of the proposed limitations of left ventricular assist device (LVAD) therapy is high degree of sensitization. Apart from human leukocyte antigen (HLA), antibodies against Angiotensin II Type 1 Receptor (AT1R) have been associated with adverse outcomes. The purpose of this study was to compare complications and survival of anti - AT1R positive versus negative Heart Mate II (HMII) recipients. METHODS: Altogether 96 patients received HMII at our institution between 2008 and 2012. These were stratified into three groups: antibody positive before implantation (AT1R+), antibody conversion during support (AT1R-/+) and patients who remained antibody negative (AT1R-). Survival, major on-device adverse events and post-transplant rejections were assessed with Kaplan-Meier and log-rank tests. RESULTS: Two year on-device and overall survival was 78 ± 12% and 75 ± 10% in AT1R-, 60 ± 23% and 60 ± 15% in AT1R+ and 92 ± 6% and 87 ± 5% in AT1R-/+ group (P = 0.409, P = 0.185). Freedom from major adverse event at two years for AT1R-, AT1R+ and AT1R-/+ was 49 ± 14%, 53 ± 16% and 41 ± 11% (P = 0.875). Freedom from rejection was 63 ± 17% in patients who were both anti-AT1R and HLA negative and 65 ± 13% in those who were antibody positive (P = 0.788). CONCLUSION: Patients who were anti-AT1R antibody positive had similar on-device survival and rate of complications in comparison to those who were antibody negative. In transplanted patients, there were no differences in the overall survival and rejection between the groups.
650    _2
$a dospělí $7 D000328
650    _2
$a protilátky $x metabolismus $7 D000906
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a rejekce štěpu $x imunologie $7 D006084
650    _2
$a HLA antigeny $x imunologie $7 D006680
650    _2
$a srdeční selhání $x imunologie $x mortalita $x terapie $7 D006333
650    _2
$a transplantace srdce $x mortalita $7 D016027
650    _2
$a podpůrné srdeční systémy $x škodlivé účinky $7 D006353
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nemoci nervového systému $x etiologie $x mortalita $7 D009422
650    _2
$a pooperační krvácení $x etiologie $7 D019106
650    _2
$a selhání protézy $7 D011475
650    _2
$a infekce spojené s protézou $x etiologie $x mortalita $7 D016459
650    _2
$a receptor angiotensinu typ 1 $x imunologie $7 D044140
650    _2
$a transplantační imunologie $x imunologie $7 D014181
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Slavčev, Antonij $u Department of Clinical Immunology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $7 xx0060517
700    1_
$a Gazdič, Tomáš $u Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $7 xx0210911
700    1_
$a Ivak, Peter $u Department of Cardiac Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Netuka, Ivan, $u Department of Cardiac Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $d 1973- $7 xx0074183
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czech Republic $x 1213-8118 $g Roč. 160, č. 4 (2016), s. 518-523
910    __
$a ABA008 $b A 1502 $c 958 $y 4 $z 0
990    __
$a 20170516 $b ABA008
991    __
$a 20170517114002 $b ABA008
999    __
$a ok $b bmc $g 1205838 $s 977507
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 160 $c 4 $d 518-523 $e 20160427 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
LZP    __
$b NLK118 $a Pubmed-20170516

Find record

Citation metrics

Archiving options